<huc>A</huc>Yes, if the estrogen is oral estradiol and it is used for 5 years or longer. When Lyytinen and colleagues studied different estrogen doses, constituents, and routes of administration in a cohort representing the entire postmenopausal population of Finland, they found an additional 2 to 3 cases of breast cancer for every 1,000 women when oral estradiol was used for 5 years or more. When it was used for a shorter time, or when the estrogen was oral estriol or a vaginal formulation, there was no increase in risk.
Statistical modeling cannot adequately account for the multiple variables involved in complex conditions such as breast cancer. For example, the GAIL model, which is used to predict an individual’s chance of having breast cancer, will only correctly score 59% of women with cancer; 41% of women with cancer will have a lower score estimate than their cancer-free cohorts. In short, “current breast cancer risk prediction models perform well for populations but poorly for individuals.”1
Breast cancer is not a single disease
Estrogen-related breast cancer is preceded histologically by atypical epithelial hyperplasia that progresses to invasive disease in some but not all women. Women who develop breast cancer while taking estrogen are more likely to have immature duct epithelium that is predominantly estrogen receptor-alpha (ERα). They are also likely to be genetically susceptible to modified physiologic cell growth and estrogen-metabolizing pathways in response to various environmental carcinogens or oncogenic promoters. In this context, exogenous estrogen may be a promoter, but not an instigator, of breast cancer.
A deficiency of vitamin D also plays a role. Vitamin D has potent antiproliferative effects that include the differentiation of breast tissue, enhanced apoptosis, and inhibition of cancer cell growth.
Untreated women with breast cancer have higher tissue levels of estrogen, which are correlated with increased breast-tissue enzymatic activity (aromatase, sulfatase, and 17β-OH dehydrogenase), especially in women with a genetic predisposition to increased or aberrant breast-tissue estrogen synthesis and metabolism. Other inherent factors include gene mutation involving cell-cycle growth (BRCA1, BRCA2, p53), and the ratio and expression of estrogen receptors; estrogen-therapy-associated breast cancer is more prevalent in women with a predominant ERα/ERβ ratio.
Mammographic density reflects the breast’s hormonal environment, the influence of background genetics, and the effect of various types, dosages, and routes of exogenous estrogen.
Not all estrogen is bioavailable
About 95% of orally administered estradiol is metabolized to estrone, estrone sulfate, and estradiol glucoronide. The bioconversion of these pro-hormones to more potent estradiol is dependent on the estrogen-metabolizing enzymes noted previously, the dose of estrogen, and the route of administration. Only 5% of orally administered estradiol is bioavailable. Because of the hepatic first-pass effect, 1 mg of oral 17β-estradiol and 25 μg of transdermal estrogen yield equivalent levels of free serum estradiol.
Variability in these and unknown factors account for the differing results of population-based studies and meta-analyses. It also may explain why, in a randomly selected group of Finnish women, only 2 to 3 extra cases of breast cancer for every 1,000 women were detected after 10 years of estrogen therapy, and at a dose twice that currently recommended.
Timing is critical, too
In the estrogen-alone arm of the Women’s Health Initiative, women aged 50 to 59 years—who are most likely to be treated with estrogen in everyday clinical practice—derived cardiovascular protection (hazard ratio [HR], 0.56), reduced colorectal cancer incidence, and a reduction in breast cancer (HR, 0.72). In contrast, most of the women in the study by Lyytinen and colleagues were over age 60. Other important risk factors not noted in their study include parity (pregnancy induces differentiation and maturation of breast ductal epithelium), pretreatment mammographic density, and vitamin D status.
- Conduct a full clinical evaluation before initiating estrogen therapy
- Assess mammographic density before and after initiation of estrogen therapy. If density increases, stop therapy or reduce the dosage and repeat mammography in 3 to 6 months
- Measure high-sensitivity serum estradiol in women at high risk. Values in excess of 10 pg/dL may reflect an increased risk of breast cancer in untreated women—although no particular level of concern has been definitively identified
- Individualize dose and length of therapy according to age and indication.
Arbitrary restriction of estrogen therapy to 5 years is not biologically rational or clinically justifiable.